title: Purslane Extract and Glucose Homeostasis in Adults with Type 2 Diabetes: A Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety.
abstract: Purslane extract (PE) is derived from Portulaca oleracea L., a medicinal plant used in traditional medicine for its antidiabetic properties. This randomized, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PE in improving glucose control, blood pressure, and lipid profile in adults with type 2 diabetes mellitus (T2DM) treated with a single oral hypoglycemic agent at baseline. Subjects were randomized to treatment with three capsules of PE/day or a matched placebo. Change from baseline to the week 12 end-of-follow-up visit measures of glucose homeostasis, hemodynamics, and lipid profile was compared by treatment assignment. In addition, these measures were evaluated in a subgroup of "responders," defined as patients whose week 12 HbA1c was lower than baseline values, regardless of treatment assignment. This group was further assessed in subgroups of baseline oral hypoglycemic treatment. A total of 63 participants were treated with either PE (n = 31, 11 females, mean age 52.4 ± 7.9 years) or matched placebo (n = 32, 11 females, mean age 58.3 ± 10.8 years). In the total cohort, systolic blood pressure declined significantly more in the PE group than the placebo group: -7.5 ± 5.0 versus -0.01 ± 0.3 mmHg, P < .0001. In the responders' subgroup, HbA1c declined significantly more in the PE group than the placebo group: -0.8% ± 0.4% versus -0.6% ± 0.5%, P = .03. Few adverse events were reported. These were mild and did not differ by treatment assignment. PE appears to be a safe, adjunct treatment for T2DM, significantly reducing systolic blood pressure in the total cohort and HbA1c in the subgroup of responders.
authors: 1 Diabetes Unit, E. Wolfson Medical Center , Holon, Israel .
authors: Julio
authors: J
authors: Wainstein
authors: 1 Diabetes Unit, E. Wolfson Medical Center , Holon, Israel .
authors: Zohar
authors: Z
authors: Landau
authors: 1 Diabetes Unit, E. Wolfson Medical Center , Holon, Israel .
authors: Yosefa
authors: Y
authors: Bar Dayan
authors: 1 Diabetes Unit, E. Wolfson Medical Center , Holon, Israel .
authors: Daniela
authors: D
authors: Jakubowicz
authors: 2 Frutarom Switzerland Ltd. , Wadenswil, Switzerland .
authors: Torsten
authors: T
authors: Grothe
authors: 2 Frutarom Switzerland Ltd. , Wadenswil, Switzerland .
authors: Tania
authors: T
authors: Perrinjaquet-Moccetti
authors: 3 Department of Nutrition, School of Health Sciences, Ariel University , Ariel, Israel .|4 Epidemiology and Research Unit, E. Wolfson Medical Center , Holon, Israel .
authors: Mona
authors: M
authors: Boaz
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006706:Homeostasis / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage*; D031822:Portulaca / Q000737:chemistry*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010936:Plant Extracts
keywords: purslane; randomized clinical trial; type 2 diabetes